Aptar's Russian Unit Write-Off Cuts Third-Quarter Earnings To $0.51 A Share, From $1.92

Adjusted earnings of $1.52 a share landed at the higher end of guidance as sales rose 6% to $1.02 billion.

Share
Aptar's Russian Unit Write-Off Cuts Third-Quarter Earnings To $0.51 A Share, From $1.92

Aptar, which makes dispensing and drug-delivery technologies, saw third-quarter net income fall to $33 million, or $0.51 a diluted share against $1.92 a year earlier, after it deconsolidated its Russian subsidiary, the company said Thursday. Sales still rose 6% to $1.02 billion, with growth in all three segments.

A $60.4 million hit from Russia

A governmental decree placed the Russian subsidiary under external administration, and Aptar lost control of it. The company booked a $58.0 million loss on deconsolidation, which included about $30.0 million of cash held by the unit.

Counting about $2.6 million of related receivable reserves and $0.5 million of legal costs, the combined impact was $61.2 million before tax and $60.4 million after tax, or $0.94 a diluted share. The reported tax rate was 45.6%, inflated by the non-deductible deconsolidation, against an adjusted rate of 23.4%.

Excluding special items, adjusted earnings were $1.52 a share, at the higher end of the company's guidance range, versus $1.62 a year earlier at comparable exchange rates. The adjusted EBITDA margin (earnings before interest, taxes, depreciation and amortization, adjusted) slipped to 21.3% from 23.2%.

Closures leads, Pharma masks destocking

Aptar designs dispensing pumps, closures, aerosol valves and injectable packaging components for drug and consumer brands, and reports in three segments.

  • Closures: reported sales rose 11% and core sales 11%, led by bottled water, concentrates and a new beverage dispensing closure; margin fell to 15.5%.
  • Beauty: reported sales rose 9% and core sales 8%, on prestige fragrance, color cosmetics and hair care; margin fell to 11.4%, with North American operations still a challenge.
  • Pharma: reported sales rose 2% and core sales 1%, or 8% excluding emergency medicine destocking; margin was 36.4%.

Total core sales rose 5%. CEO Gael Touya said the company delivered "broad-based revenue growth across all three segments" as he began his tenure.

Outlook and shareholder returns

Aptar guided fourth-quarter adjusted earnings to $1.39 to $1.47 a share, assuming a tax rate of 17.5% to 19.5%. Touya said he expects the company to "finish the year strong," without the emergency medicine destocking drag.

The company returned $61 million to shareholders in the quarter and $272 million for the year to date through buybacks and dividends. Its board raised the quarterly dividend to $0.50 from $0.48, payable December 3 to holders of record on November 12.

For the nine months, reported earnings were $3.00 a share versus $4.75, while adjusted earnings were $4.13 versus $4.60.

Aptar holds its earnings call Friday, October 30, at 8:00 a.m. Central Time.

Sources